Annovis Bio Names Mark Guerin CFO as Buntanetap Nears Late-Stage Milestones

Annovis Bio Names Mark Guerin CFO as Buntanetap Nears Late-Stage Milestones

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer, bringing on a seasoned financial leader to guide the company through a crucial stage as its lead candidate, buntanetap, advances in late-stage clinical development. Guerin joins Annovis with more than two decades of financial leadership in biopharma. Most recently, he served as CFO of Onconova Therapeutics, now Traws Pharma, Inc. (N…